OBJECTIVE: To determine if systemic corticosteroid therapy is associated with improved outcomes for children hospitalized with community-acquired pneumonia (CAP). METHODS: In this multicenter, retrospective cohort study we used data from 36 children's hospitals for children aged 1 to 18 years with CAP. Main outcome measures were length of stay (LOS), readmission, and total hospitalization cost. The primary exposure was the use of adjunct systemic corticosteroids. Multivariable regression models and propensity scores were used to adjust for confounders. RESULTS: The 20 703 patients whose data were included had a median age of 4 years. Adjunct corticosteroid therapy was administered to 7234 patients (35%). The median LOS was 3 days, and 245 patients (1.2%) required readmission. Systemic corticosteroid therapy was associated with shorter LOS overall (adjusted hazard ratio [HR]: 1.24 [95% confidence interval (CI): 1.18-1.30]). Among children who received treatment with β-agonists, the LOS was shorter for children who had received corticosteroids compared with children who had not (adjusted HR: 1.36 [95% CI: 1.28-1.45]). Among children who did not receive β-agonists, the LOS was longer for those who received corticosteroids compared with those who did not (adjusted HR: 0.85 [95% CI: 0.75-0.96]). Corticosteroids were associated with readmission of patients who did not receive concomitant β-agonist therapy (adjusted odds ratio: 1.97 [95% CI: 1.09-3.57]). CONCLUSIONS: For children hospitalized with CAP, adjunct corticosteroids were associated with a shorter hospital LOS among patients who received concomitant β-agonist therapy. Among patients who did not receive this therapy, systemic corticosteroids were associated with a longer LOS and a greater odds of readmission. If β-agonist therapy is considered a proxy for wheezing, our findings suggest that among patients admitted to the hospital with a diagnosis of CAP, only those with acute wheezing benefit from adjunct systemic corticosteroid therapy.
OBJECTIVE: To determine if systemic corticosteroid therapy is associated with improved outcomes for children hospitalized with community-acquired pneumonia (CAP). METHODS: In this multicenter, retrospective cohort study we used data from 36 children's hospitals for children aged 1 to 18 years with CAP. Main outcome measures were length of stay (LOS), readmission, and total hospitalization cost. The primary exposure was the use of adjunct systemic corticosteroids. Multivariable regression models and propensity scores were used to adjust for confounders. RESULTS: The 20 703 patients whose data were included had a median age of 4 years. Adjunct corticosteroid therapy was administered to 7234 patients (35%). The median LOS was 3 days, and 245 patients (1.2%) required readmission. Systemic corticosteroid therapy was associated with shorter LOS overall (adjusted hazard ratio [HR]: 1.24 [95% confidence interval (CI): 1.18-1.30]). Among children who received treatment with β-agonists, the LOS was shorter for children who had received corticosteroids compared with children who had not (adjusted HR: 1.36 [95% CI: 1.28-1.45]). Among children who did not receive β-agonists, the LOS was longer for those who received corticosteroids compared with those who did not (adjusted HR: 0.85 [95% CI: 0.75-0.96]). Corticosteroids were associated with readmission of patients who did not receive concomitant β-agonist therapy (adjusted odds ratio: 1.97 [95% CI: 1.09-3.57]). CONCLUSIONS: For children hospitalized with CAP, adjunct corticosteroids were associated with a shorter hospital LOS among patients who received concomitant β-agonist therapy. Among patients who did not receive this therapy, systemic corticosteroids were associated with a longer LOS and a greater odds of readmission. If β-agonist therapy is considered a proxy for wheezing, our findings suggest that among patients admitted to the hospital with a diagnosis of CAP, only those with acute wheezing benefit from adjunct systemic corticosteroid therapy.
Authors: James E Gern; Matthew S Martin; Kelly A Anklam; Kunling Shen; Kathy A Roberg; Kirstin T Carlson-Dakes; Kiva Adler; Stephanie Gilbertson-White; Rebekah Hamilton; Peter A Shult; Carol J Kirk; Douglas F Da Silva; Sarah A Sund; Michael R Kosorok; Robert F Lemanske Journal: Pediatr Allergy Immunol Date: 2002-12 Impact factor: 6.377
Authors: Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore Journal: Clin Infect Dis Date: 2002-01-03 Impact factor: 9.079
Authors: G Umberto Meduri; Elizabeth A Tolley; George P Chrousos; Frankie Stentz Journal: Am J Respir Crit Care Med Date: 2002-04-01 Impact factor: 21.405
Authors: Hong Wei Chu; Jennifer A Campbell; John G Rino; Ronald J Harbeck; Richard J Martin Journal: J Infect Dis Date: 2004-03-02 Impact factor: 5.226
Authors: Ian C Michelow; Kurt Olsen; Juanita Lozano; Nancy K Rollins; Lynn B Duffy; Thedi Ziegler; Jaana Kauppila; Maija Leinonen; George H McCracken Journal: Pediatrics Date: 2004-04 Impact factor: 7.124
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079
Authors: Mary Ann Queen; Angela L Myers; Matthew Hall; Samir S Shah; Derek J Williams; Katherine A Auger; Karen E Jerardi; Angela M Statile; Joel S Tieder Journal: Pediatrics Date: 2013-12-09 Impact factor: 7.124
Authors: Lilliam Ambroggio; Matthew Test; Joshua P Metlay; Thomas R Graf; Mary Ann Blosky; Maurizio Macaluso; Samir S Shah Journal: J Pediatric Infect Dis Soc Date: 2014-03-27 Impact factor: 3.164
Authors: Harriet E Downing; Fran Carroll; Sara T Brookes; Sandra Hollinghurst; David Timmins; Elizabeth Orton; Kay Wang; Denise Kendrick; Paul Little; Mike V Moore; Anthony Harnden; Matthew Thompson; Margaret T May; Alastair D Hay Journal: Trials Date: 2015-03-07 Impact factor: 2.279